NetworkNewsBreaks – CytoDyn Inc. (CYDY) Interim CMO to Present at 11th Annual Conference on Stem Cell and Regenerative Medicine

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning announced that Richard G. Pestell, M.D., Ph.D., president of the Pennsylvania Cancer and Regenerative Medicine Research Center, distinguished professor at the Baruch S. Blumberg Institute and interim chief medical officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine in Helsinki, Finland. Pestell’s presentation, titled ‘Cancer stem cells, genetic drivers and therapeutic targeting via CCR5’, is scheduled to take place on Monday, October 15, from 10-11 am EEST. Pestell will present recent scientific evidence demonstrating the effectiveness of PRO 140 (leronlimab), which is shown to bind to CCR5 in human breast cancer, block CCR5 signaling induced by cytokines and block human breast cancer cell invasion.

To view the full press release, visit http://nnw.fm/SgzM0

About CytoDyn

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com

More from NetworkNewsBreaks

NetworkNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Adds Taxation Reporting Technology to its Proprietary Compliance Platform NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Announces Results of Independent Studies Supporting Restart of Canadian Refinery NetworkNewsBreaks – The Flowr Corporation (TSX.V: FLWR) Ships Initial Purchase Order from the NSLC

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.

Latest News

Versace to Emporio: Men's looks shine, literally, in Milan

Jun 25, 2019

MILAN — Milan Fashion Week for spring/summer menswear previews has started with a slightly different rhythm, with many mainstays not showing this season. It is a sign of the times that fashion houses are seeking new ways to reach their audiences, and slotting menswear into womenswear shows by now is old hat. Gucci and Bottega Veneta are among the houses choosing that path, and skipping the June round of shows. And this year, Pitti Uomo in Florence got a boost as the chosen venue for Ferragamo, which normally shows in Milan, and Givenchy, which makes Paris its home. Prada went...

The Latest: Death toll rises to 19 in Danube tour boat crash

Jun 25, 2019

BUDAPEST, Hungary — The Latest on the fatal Danube River boating accident in Hungary's capital (all times local): 10:45 p.m. Hungarian police say the death toll from the tour boat that capsized and sank last week after colliding in Budapest with a cruise ship has risen to 19. Police said the bodies of a female South Korean tourist and one of the two Hungarian crewmen were recovered Thursday. Eight South Koreans and the other crew member are still missing. Only seven tourists aboard the Hableany (Mermaid) are known to have survived the May 29 crash. Efforts to lift the Hableany...

5 injured in Venice as cruise ship slams into tourist boat

Jun 25, 2019

VENICE, Italy — A towering, out-of-control cruise ship rammed into a dock and a tourist riverboat on a busy Venice canal on Sunday morning, injuring five people, officials said. The collision sparked new calls for placing restrictions on cruise ships in the famed city. The crash happened about 8:30 a.m. (0630 GMT) on the Giudecca Canal, a major thoroughfare that leads to St. Mark's Square in the northeastern Italian city. The MSC Opera cruise ship, apparently unable to stop, blared its horn as it slammed into the much smaller River Countess boat and the dock as dozens of people ran...

The Latest: Seoul says tourists did not wear life jackets

Jun 25, 2019

BUDAPEST, Hungary — The Latest on a boat that capsized in the Danube River in Budapest with 33 South Korean tourists (all times local): 7:50 a.m. South Korean Foreign Ministry says South Korean tourists in the deadly boat collision in Budapest weren't wearing life jackets. Officials in Seoul say seven South Korean tourists are dead and 19 others remain missing after their sightseeing boat collided with a larger cruise ship and capsized Wednesday night in the Danube River. Seven South Koreans have been rescued. The Foreign Ministry says South Korean diplomats in Hungary have learned the tourists did not put...

Venice Biennale invites heavy thinking on political issues

Jun 25, 2019

VENICE, Italy — Fake news. Migration. Poverty. Global warming. Armed conflict. Political issues that excite newsprint, the airwaves and social media are getting a very open airing at the 58th Venice Biennale contemporary art fair, like so much laundry hung out to dry in the lagoon breeze. American curator Ralph Rugoff, director of London's Hayward Gallery, titled the main exhibition "May You Live in Interesting Times," which opens Saturday and runs through Nov. 24. The title is itself an exemplary piece of fake news, delivered by a British lawmaker as Europe hurled toward World War II as an ancient Chinese...

Sign up now!

The Healthier Web delivers accurate and up-to-date health information through medical content and insights from experts. Feel the ‘ohm’ here in The Healthier Web.

Contact us: sales[at]thehealthierweb.com